One is Tasigna, now approved for the minority chronic leukemia patients who are resistant to Gleevec.

FORBES: Magazine Article

Bristol-Myers Squibb ( BMY - news - people ) sells a drug called Sprycel that competes with Tasigna.

FORBES: Pipelines

Less than 1% of Tasigna patients progressed to more advanced disease within a year vs. an estimated 4% of patients on Gleevec.

FORBES: Magazine Article

Based on the trial, Novartis plans to apply next year for approval to market Tasigna for initial therapy for chronic myeloid leukemia.

FORBES: Pipelines

Bristol-Myers Squibb sells a drug called Sprycel that competes with Tasigna.

FORBES: Magazine Article

Over time, it hopes to convince hematologists to use Tasigna first.

FORBES: Pipelines

At a big meeting of hematologists today, Novartis unveiled data from an 846-patient trial showing that Tasigna was more effective than Gleevec in early-stage leukemia patients.

FORBES: Pipelines

After a year on therapy, 54% to 57% of patients on Tasigna had no signs of leukemia using the most sensitive test vs. just 30% of those who were on Gleevec.

FORBES: Magazine Article

In trials Tasigna sent half these patients into remission.

FORBES: Big Bucks